Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
RT @BioCentury: CDER releases guidance on liposome products https://t.co/P4huu8uQQK
SteveFDA (R-D.C.)
@SGottliebFDA
RT @US_FDA: Read FDA Commissioner @SGottliebFDA remarks @RXSummit re: strategies to reduce overall exposure to opioids w/ appro… https://t.co/l2x8ThHCVc
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: Stigma is the enemy of public health. When it comes to opioid misuse, it can stop people from seeking help. We must… https://t.co/hqTTQhySvM
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RxSummit: .@ScottGottliebMD: We need evidence-based guidelines for dosing on common procedures so the @US_FDA can regulate properly. #rxsummit
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RxSummit: .@ScottGottliebMD: @US_FDA found a single day of opiates was sufficient for most minor surgeries, like laparoscopic appendectomy #rxsummit
SteveFDA (R-D.C.)
@SGottliebFDA
RT @drJoshS: @US_FDA @SGottliebFDA @RxSummit This is an especially good idea from @SGottliebFDA — require doctors to take traini… https://t.co/cIuysI9ohL
SteveFDA (R-D.C.)
@SGottliebFDA
RT @BPC_Bipartisan: .@SGottliebFDA echoes recommendation from BPC's Governors Council to require opioid training at the time physicians… https://t.co/fWPtuOgJCg
SteveFDA (R-D.C.)
@SGottliebFDA
RT @carlquintanilla: FDA Commish speech today: "I’m concerned that social media companies, internet service providers (ISP) firms that h… https://t.co/RnRK0c4wED
SteveFDA (R-D.C.)
@SGottliebFDA
RT @steveusdin1: NIH, FDA announce opioids plans. @SGottliebFDA highlighted research on the alignment between opioid prescribing and… https://t.co/xRU8d8I7QX
SteveFDA (R-D.C.)
@SGottliebFDA
RT @MMundkur: I can’t express how excited I am that Scott Gottlieb is sharing preliminary results from the analysis that I have been leadin… QT @US_FDA: Read FDA Commissioner @SGottliebFDA remarks @RXSummit re: strategies to reduce overall exposure to opioids w/ appro… https://t.co/l2x8ThHCVc)
SteveFDA (R-D.C.)
@SGottliebFDA
To foster greater drug competition from low cost generics, especially when it comes to hard to copy complex drugs, #FDA issued guidance for development of liposomes; a class of complex drug products often used to treat life threatening diseases like cance
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: .@samhsagov Dr. McCanceKatz talks of ⬆️ risk of overdose after release from opioid disorder treatment- especially a… https://t.co/t8C6F3QEsj
SteveFDA (R-D.C.)
@SGottliebFDA
Thanks to @CNN and @drsanjaygupta for hosting #FDA yesterday while we were in Atlanta for the Rx Summitt on opioids; and for sitting down with us to discuss the many public health challenges and opportunities facing our agency https://t.co/klgAoflZ2e
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: “If you, or someone you know, is at risk for an overdose, carry and know how to use naloxone— a lifesaving, easy to… https://t.co/w6FOvpSwfX
SteveFDA (R-D.C.)
@SGottliebFDA
Important and impactful new policy from @Surgeon_General https://t.co/FydZbNQ7I3 QT @Surgeon_General: This morning, I released a Public Health Advisory on Naloxone and Opioid Overdose. Together we can end the opioid e… https://t.co/kN8o9TCFkw)
SteveFDA (R-D.C.)
@SGottliebFDA
Dramatically lowering smoking rates could be the single greatest public health intervention that we undertake over any reasonable period of time to reduce early death and the burden of chronic disease https://t.co/rP8lXqpvPx
SteveFDA (R-D.C.)
@SGottliebFDA
RT @Surgeon_General: “Today in America, addiction is a public health crisis. An estimated 2.1 million people in the U.S. struggle with a… https://t.co/jYNoGCcAPn
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDADeviceInfo: CDRH is honored to have 86 members of #USPHS #CommissionedCorps working hard, every day, to help us reach our missi… https://t.co/yvcGoq3hVx
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA has approved both auto-injector/intranasal forms of naloxone for use by first responders, community-based organizations and friends/family of opioid users. We’re also working on ways to assist manufacturers in submitting an application for an OTC ver